Sr. Director, MASH/ALD Brand Lead & Pipeline

Position Summary

The role serves as the commercial Brand Lead for MASH/ALD assets and as the primary U.S. commercial authority for the broader Hepatology/Immunology pipeline and portfolio. The role has end-to-end accountability for pipeline strategy from early development through launch readiness and lifecycle management.

Key Responsibilities

• Serve as the commercial and Brand Lead for MASH/ALD assets, owning and shaping the commercial strategy and leading cross-functional commercial planning and launch-readiness activities.
• Own U.S. pipeline and portfolio strategy for Hepatology/Immunology assets, establishing the commercial vision and prioritization logic that guide investment and launch-readiness decisions from Phase 2 through Local Operating Company (LOC) activation.
• Define and deliver U.S. market analyses, competitive assessments, and commercial assumptions for Hepatology/Immunology pipeline assets.
• Serve as the single point of accountability for U.S. commercial input at early stage-gates, representing the voice of U.S. HCPs, patients, and payers in development decisions.
• Build and own the pre-launch commercial foundation for priority Hepatology/Immunology pipeline assets, including input to the target product profile (TPP), positioning hypotheses, customer segmentation frameworks, and initial value proposition development.
• Deliver stage-gate recommendations to global teams for Phase 2, 2b, and 3 decisions, clearly articulating the U.S. commercial opportunity, risk, and go/no-go rationale.
• Establish and evolve a long-range portfolio vision for Hepatology/Immunology, including asset prioritization, sequencing, and strategic planning.
• Lead U.S. portfolio and lifecycle strategy across in-line and pipeline Hepatology/Immunology assets, ensuring consistency across brand strategy, commercial objectives, and Medical-owned strategy.
• Develop market maps for the current and future Hepatology/Immunology portfolio, accounting for customer and patient needs, financial impacts, and the evolving healthcare landscape.
• Create and implement portfolio strategies in partnership with global counterparts, including U.S.-specific initiatives.
• Translate commercial and environmental assessments into forward-looking insights on how patient, marketplace, and customer needs may evolve.
• Leverage insights from in-line brand performance, customer experience, external experts, and competitive trends to inform portfolio strategy, indication prioritization, and lifecycle management.
• Maintain an evolving perspective on reimbursement trends and market access dynamics to inform pipeline, commercial, and portfolio strategy.
• Develop and maintain deep expertise in the brand narrative, disease landscape, competitive dynamics, and customer segments for priority assets.
• Work alongside U.S. Health Outcomes, Medical Affairs, and Market Access to maintain a working command of the clinical, health outcomes, and economic evidence supporting brand value positioning and early payer strategy.
• Evaluate and recommend innovative go-to-market models for Hepatology/Immunology medicines, including differentiated approaches to customer engagement, channel strategy, and P&L optimization.
• Serve as the primary U.S. commercial authority at global governance forums, including the Forecast Review Committee (FRC), Portfolio Investment Board (PIB), and relevant stage-gate committees.
• Function as a delegated U.S. commercial decision-maker and strategic advisor to the Marketing VP for pipeline- and portfolio-related decisions.
• Build and maintain strong relationships with strategy and business unit leadership to ensure consistent U.S. input into global portfolio and pipeline decisions.
• Evaluate business development opportunities relevant to the U.S. Hepatology/Immunology portfolio and provide commercially grounded recommendations.
• Own the pipeline and portfolio strategy budget, including market research, competitive intelligence, and pipeline analytics.
• Collaborate with Forecasting & Finance to ensure an accurate outlook for U.S. Hepatology/Immunology launches, develop financial assumptions for pipeline assets, and identify additional value opportunities.
• Provide strategic leadership across pipeline strategy and early commercialization, establishing clear direction, high standards, and effective ways of working across cross-functional teams.
• Set and maintain high standards for analytical rigor, commercial thinking, and stakeholder engagement.
• Contribute actively to succession planning, talent development, and organizational health across the Hepatology/Immunology commercial organization.
• Collaborate with senior leaders across U.S. business units, Global Therapy Areas, Therapy Area Research Leaders, Medical Development Leads, Forecasting & Finance, Health Outcomes, and Business Development.
• Lead cross-functional commercial planning for MASH/ALD and build and maintain strong relationships with Brand Leads, Medical Affairs, Market Access, and Commercial Leadership.
• Work seamlessly across key stakeholders in Sales, Insights & Analytics, Finance, Medical, and Global Product Strategy (GPS).